Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
37. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the methabolic syndrome, and risk of incident cardiovascular events: an 8-years follow-up of 14719 initially healthy American women. Circulation 2003; 107: 391—397.
38. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothe-
SHS-OOO4.qxd 21.11.2006 16:56 Page 2995
95
ГЛАВА 11. Иммунологические маркеры атеросклероза
lial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107: 398—404.
39. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, anf risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 2003; 107: 391—397.
40. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499—511.
41. Executive Summary of The Third Report of THE National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486—2497.
42. Malle E, De Beer FC. Human serum amyloid A ptotein: a promising acute-phase reactant for clinical practice. Eur J Clin Invest 1996; 26: 427—435.
43. Morrow DL, Rifai N, Antman EM, et al. Serum amyloid A predictive early mortality in acute coronary syndrome: a TIMI 11A substudy. JAm Coll Cardiol 2000; 35: 358—362.
44. Volpato S, Guralnik JM, Ferrucci L, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women. The Women s Health and aging Study. Circulation 2001; 103: 947— 953.
45. Harris TB, Ferrucci I, Traxy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506—512.
46. Biasucci LM, Vielli A, Liuzzo G. Elevated levels of IL-6 in unstable anginaw. Circulation 1996; 94: 874—877.
47. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-Ra and interleukin-6 during first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999; 98: 2079—2084.
48. Cusack M, Odemuyiwa S, Kamalvand K, et al. Can systemic markers of inflammation accu-
rately predict short-term outcome in patients with unstable coronary syndrome? J Amer Coll Cardiol 2001; 37 (Suppl.A): 359A.
49. Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 24—30.
50. Фукс Д, Самсонов МЮ, Насонов ЕЛ, Беленков ЮН. Клиническое значение неоптерина при заболеваниях человека. Терапевт. архив, 1993; 5: 80—87.
51. Fuchs D. Neopterin. A massage from the immune system. 1998. BRAHMS Diagnostic GmbH.
52. Насонов ЕЛ, Самсонов М.Ю, Тилз Г, Фукс Д. Неоптерин: новый иммунологический маркер аутоиммунных ревматических заболеваний. Клин. медицина, 2000; 8: 43—46.
53. Koglin J, Methe H, Brunner S. et al. Expression of interferon-gamma-producing Th1 lymphocytes as a mechanism of progression in acute coronary syndrome. Am J Cardiol 2001; 37: 317A—318A.
54. Liuzo G, Kopecky SL, Frye RL, et al. Perturbation of the T-cell repertuar in patients with unstable angina. Circulation 1999; 100: 2135—2139.
55. Weiss G, Willei J, Kiechl S, et al. Increased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis 1994; 106: 263—271.
56. Schumacher M, Halwachs G, Tatzber F, et al. Increased neopterin in patients with chronic and acute coronary syndrome. J Amer Coll Cardiol 1997; 30: 703—707.
57. Garcia-Moll N, Coccolo, Cole D, et al. Serum neopterin and complex stenosis morphology in patients with unstable angina. J Amer Coll Cardiol 2000; 35: 956—962.
58. Tatzler F, Rabl H, Koriska K, et al. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis 1991; 89: 203—208.
59. Schuacher M, Eber B, Tatzber F, et al. Neopterin levels in patients with coronary artery disease. Atherosclerosis 1992; 94: 87—88.
60. Erren M, Reinecke H, Junker, et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Biol 1999; 19: 2355—2363.
SHS-OOO4.qxd 21.11.2006 16:56 Page 296
Насонов Е.Л. Антифосфолипидный синдром.
61. Melichar B, Gregor J, Solochova D, et al. Increased urinary neopterin in acute myocardial infarction. Clin Chem 1994; 40: 38—339.
62. Gupta S, Fredericks S, Schwartzman RA, et al. Serum neopterin in acute coronary syndrome. Lancet 1997; 349: 1252—1253.
63. Gurfinkel EP, Scirica BM. Borovich G, et al. Serum neopterin levels and the angiographic extent of coronary arterial narrowing in instable angina pectoris and in non-Q wave acute myocardial infarction. Am J Cardiol 1999; 83: 515—518.
